Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

ClinicalTrials.gov ID: NCT00120393

Public ClinicalTrials.gov record NCT00120393. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIIB, Open-label, Randomized, Multi-center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r Based Regimen.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).

Study identification

NCT ID: NCT00120393
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 192 participants

Conditions and interventions

Conditions

HIV Infections

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2004 (Type not available)
Primary completion: May 2006 (Actual)
Completion: May 2006 (Actual)
Last update posted: Feb 5, 2010

2004 – 2006

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Local Institution	Phoenix	Arizona	—	—
Local Institution	Bakersfield	California	—	—
Local Institution	Los Angeles	California	—	—
Local Institution	San Francisco	California	—	—
Local Institution	Miami	Florida	—	—
Local Institution	Boston	Massachusetts	—	—
Local Institution	New York	New York	—	—
Local Institution	Cincinnati	Ohio	—	—
Local Institution	Portland	Oregon	—	—
Local Institution	Philadelphia	Pennsylvania	—	—
Local Institution	Columbia	South Carolina	—	—
Local Institution	Dallas	Texas	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00120393, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 5, 2010 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00120393 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →